Indivumed appoints Harald Eistetter as Chief Business Officer and Managing Director
Indivumed GmbH announced the appointment of Harald R Eistetter, PhD, as Managing Director and to the newly created position of Chief Business Officer.
Dr Eistetter, who has more than two decades of leadership experience in the pharmaceutical and biotech industry, will be responsible in particular for further developing and implementing Indivumed's corporate strategy and commercial potential. He joins from The Genetics Company Inc., a Zurich, Switzerland, based drug and diagnostics discovery company, where he served as Chief Executive Officer for the past six years. Dr. Eistetter started his professional career with Altana Pharma and subsequently held several senior and international management positions within Glaxo and BASF Pharma. His interests are in the fields of oncology and neuroscience and he received his PhD in Genetics from the University of Tuebingen, Germany in 1985.
Organizations
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Last viewed contents
NascaCell announces an aptamer distribution agreement in Japan with GE Healthcare
XOMA Announces Planned Retirement of Chief Executive Officer
East German physicians prescribe significantly more high-priced biopharmaceutical medication than West German doctors - 127% higher revenues of pharmaceutical companies per physician and year in the area of former East Germany
Apeiron announces start of phase I trail with cellular anti cancer therapy
Tecan and the Monash Antibody Technologies Facility unveil custom monoclonal antibody production facility
Acacia Pharma starts clinical trial with APD515 for Xerostomia

Innovative therapeutic tools in the fight against cancer - Spin-off company of the University Medical Center Mainz starts operations and enters into joint venture with Indivumed
Cardio3 BioSciences Appoints Dr. Alexander Milstein as Vice President of Clinical Development
Dr. Andrew Zhu Joins Chemokine Therapeutics' Clinical Advisory Board
Gilead Sciences to Acquire Pharmasset, Inc. for $11 Billion
MediGene Initiates Clinical Formulation Study of RhuDex for the Oral Treatment of Autoimmune Diseases
